DermaPure Non-Oriented has two identical sides, meaning the orientation of the graft is not a factor during implantation, making it easier to apply.
It will be used in uro-gynecological (female pelvic medicine) and will be sold by partner and specialist distributor, ARMS Medical.
Interim chief executive Gareth Jones said: “Our commercial success is predicated on our ability to identify new clinical applications and rapidly develop product lines to meet this demand.
“Working closely with our strategic partner, ARMS Medical, we are confident that DermaPure Non-Oriented will offer our clinicians the clinical outcomes and health economic benefits they require.
“We continue to see the growing demand for DermaPure, as demonstrated in our recent interim results, and expect that DermaPure Non–Oriented will augment this product portfolio, driving adoption by physicians in the future.”